Advocating for Preservative-free Glaucoma Drops to Improve Ocular Health

Overview

The Preservative Freedom Coalition (PFC) promotes awareness of the ocular surface damage caused by preservatives in glaucoma medications and advocates for preservative-free alternatives. These preservative-free drops improve patient comfort, reduce ocular irritation, and may enhance treatment adherence and outcomes.

Background

Preservatives such as benzalkonium chloride (BAK) are commonly used in topical ophthalmic medications to prevent contamination but have been linked to ocular surface toxicity, inflammation, and corneal damage, especially in patients requiring lifelong glaucoma treatment. The PFC, founded in 2023, includes major glaucoma organizations and aims to educate physicians and patients about the benefits of preservative-free eye drops. Long-term use of preserved drops can lead to symptoms like redness, irritation, and tearing, which negatively impact patient compliance and ocular health.

Data Highlights

Denmark passed legislation in 2023 prohibiting substitution of brand-name preservative-free eye drops with generic BAK-containing versions, reflecting growing recognition of preservative toxicity. Although preservative-free medications are currently more expensive, advocacy efforts are underway to improve affordability and insurance coverage through prior authorization processes.

Key Findings

• Preservatives in glaucoma drops, particularly BAK, cause ocular surface damage, inflammation, redness, irritation, and corneal staining.
• Preservative-free glaucoma medications improve patient comfort by reducing burning, stinging, redness, blurred vision, and tearing.
• Improved ocular surface health with preservative-free drops enhances tear production and tear break-up time.
• Removing preservatives can improve drug efficacy by reducing ocular toxicity and increasing patient adherence.
• Patient education and physician advocacy are critical to increasing use of preservative-free options.
• Cost remains a barrier, but prior authorization and advocacy efforts may improve access to preservative-free glaucoma treatments.

Clinical Implications

Clinicians should consider prescribing preservative-free glaucoma medications to minimize ocular surface toxicity and improve patient comfort and adherence. Educating patients about the benefits of preservative-free drops empowers them to advocate for safer treatment options. Awareness of insurance prior authorization pathways can facilitate access despite higher costs.

Conclusion

Preservative-free glaucoma drops represent a valuable advancement in managing ocular surface health and treatment tolerability. Increased awareness, education, and advocacy are essential to integrating these safer alternatives into routine glaucoma care.

References

1. Preservative Freedom Coalition/Glaucoma Foundation/2023 -- Advocating for Preservative-free Glaucoma Drops